Remission Clinical Trials

54 recruitingLast updated: June 18, 2026

There are 54 actively recruiting remission clinical trials across 23 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1. Top locations include Seattle, Washington, United States, Paris, France, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Remission Trials at a Glance

54 actively recruiting trials for remission are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Not Applicable with 21 trials, with the heaviest enrollment activity in Seattle, Paris, and Boston. Lead sponsors running remission studies include The First Affiliated Hospital of Soochow University, University of Padova, and Assistance Publique - Hôpitaux de Paris.

Browse remission trials by phase

Treatments under study

About Remission Clinical Trials

Looking for clinical trials for Remission? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Remission trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Remission clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 54 trials

Recruiting
Not Applicable

Mechanisms of Change of Positive Interventions in Reducing Vulnerability for Depression

Depression in Remission
University Medical Center Groningen100 enrolled1 locationNCT06145984
Recruiting
Phase 1Phase 2

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell NeoplasmAcute Myeloid Leukemia in RemissionChronic Myelomonocytic Leukemia+9 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT03670966
Recruiting
Not Applicable

Drinking, Acetate, and Stress

Alcohol Use DisorderAlcohol Use, UnspecifiedHeavy Drinker+1 more
Yale University50 enrolled2 locationsNCT06584448
Recruiting
Not Applicable

Neuroimaging of Adolescent Cannabis Use Treatment

Cannabis withdrawalSubstance Use DisordersCannabis Use+23 more
Indiana University80 enrolled1 locationNCT07340554
Recruiting
Phase 2

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Chronic Lymphocytic LeukemiaHodgkin LymphomaMyeloma+4 more
University Hospital, Clermont-Ferrand150 enrolled20 locationsNCT04935684
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

OsteosarcomaRecurrent LymphomaLymphoblastic Lymphoma+4 more
Children's Oncology Group420 enrolled79 locationsNCT01790152
Recruiting
Not Applicable

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

LeukemiaAcute Myeloid Leukemia in RemissionLymphoblastic Lymphoma+10 more
Medical College of Wisconsin40 enrolled1 locationNCT05794880
Recruiting

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

CancerSurvivorshipRecurrent+2 more
Memorial Sloan Kettering Cancer Center1,000 enrolled4 locationsNCT07030686
Recruiting

Association Between LRG and Histologic Remission in Ulcerative Colitis

Ulcerative Colitis in Histologic Remission
Showa Inan General Hospital100 enrolled1 locationNCT06372613
Recruiting
Phase 1

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission
Shenzhen Geno-Immune Medical Institute20 enrolled1 locationNCT06006741
Recruiting
Phase 1Phase 2

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Acute Lymphoblastic Leukemia With Failed Remission
The First Affiliated Hospital of Soochow University196 enrolled1 locationNCT03919240
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Not Applicable

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia RefractoryAcute Lymphoblastic Leukemia With Failed Remission+2 more
King Hussein Cancer Center12 enrolled1 locationNCT07371403
Recruiting
Phase 1Phase 2

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission
Georgetown University24 enrolled3 locationsNCT04990102
Recruiting
Phase 1

Ziftomenib Maintenance Post Allo-HCT

Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionKMT2A Rearrangement+1 more
Massachusetts General Hospital22 enrolled2 locationsNCT06440135
Recruiting
Phase 1

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Acute Lymphoblastic Leukemia, in RelapseAcute Leukemia of Ambiguous LineageAcute Lymphoblastic Leukemia With Failed Remission+8 more
Andrew E. Place, MD30 enrolled5 locationsNCT05292664
Recruiting
Not Applicable

Autoimmune Intervention Mastery Course Study

Multiple SclerosisClinically Isolated SyndromeFibromyalgia+2 more
Terry L. Wahls400 enrolled1 locationNCT05057676
Recruiting
Not Applicable

Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma

Quality of LifeObjective Response RatePathological Complete Remission+1 more
The Second Hospital of Shandong University25 enrolled1 locationNCT07430579
Recruiting
Phase 2

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Acute Myeloid Leukemia in Remission
Nantes University Hospital302 enrolled23 locationsNCT05917405